Table 2.
Clinical features of IBD patients (N = 77).
| Diagnosis, n (%) | ||
|---|---|---|
| Crohn’s disease | 37 (48.1) | |
| Ulcerative colitis | 40 (51.9) | |
| Years of disease, mean (±SD) | 13.7 (±11.2) | |
| Years of disease range, n (%) | ||
| <1 | 3 (3.9) | |
| 1–5 | 26 (33.8) | |
| 6–10 | 8 (10.4) | |
| 11–15 | 12 (15.6) | |
| 16–20 | 6 (7.8) | |
| >20 | 22 (28.5) | |
| CD location, n (%) | ||
| Ileal | 10 (27.0) | |
| Colonic | 4 (10.8) | |
| Ileocolonic | 23 (62.2) | |
| Isolated upper disease | 0 (0.0) | |
| UC extent, n (%) | ||
| Proctitis | 1 (2.5) | |
| Left-sided | 15 (37.5) | |
| Extensive disease | 24 (60.0) | |
| Activity, n (%) | CD | UC |
| Quiescent | 20 (54.1) | 28 (70) |
| Mild | 12 (32.4) | 8 (20.0) |
| Moderate | 5 (13.5) | 3 (7.5) |
| Severe | 0 (0.0) | 1 (2.5) |
| BSG risk grid, n (%) | ||
| Lowest risk | 19 (24.7) | |
| Moderate risk | 49 (63.6) | |
| Highest risk | 9 (11.7) | |
| Treatment, n (%) | ||
| Biologic therapy | 34 (44.2) | |
| Conventional therapy | 43 (55.8) | |